Agile Therapeutics Inc
AGRXDelisted Jun 3, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001261249
Agile Therapeutics Inc was delisted on Jun 3, 2024; its insiders filed their last Form 4 on Aug 26, 2024; 21 institutions reported holding it in 13F filings for Q4 2023, worth $496.2K in total; no superinvestor held it.
13F holders, Q2 2024
Institutional positions in Agile Therapeutics Inc as of Jun 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
AGRX is no longer listed, and 13F filings after Q4 2023 list far fewer holders. See Q4 2023
- Institutional holders
- 0
- −1 vs. Q1 2024
- Shares held
- 0
- −1.75K (−100.0%) vs. Q1 2024
- Total value
- $0
- −$596 (−100.0%) vs. Q1 2024
- New holders
- 0
- 0 more added
- Sold out
- 1
- 0 more reduced
Compare with Q1 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting AGRX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 1 | $596 |
| Q4 2023 | 21 | $496.2K |
| Q3 2023 | 17 | $355.2K |
| Q2 2023 | 16 | $425.8K |
| Q1 2023 | 23 | $337.2K |
| Q4 2022 | 27 | $371.5K |
| Q3 2022 | 28 | $683.0K |
| Q2 2022 | 21 | $1.28M |
| Q1 2022 | 39 | $4.04M |
| Q4 2021 | 47 | $18.4M |
| Q3 2021 | 54 | $30.5M |
| Q2 2021 | 71 | $45.7M |
| Q1 2021 | 78 | $79.6M |
Institutions, Q2 2024
Shares, value and share of portfolio for each institution holding Agile Therapeutics Inc; share changes are against Q1 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Investor AB | 0 | $0 | 0.00% | −1,754−100.0% | Sold out |